Enhanced Vascularization of VEGF Synergizing with 2-N,6-o-sulfated Chitosan
Yu Yuanman,Chen Rui,Peng Xiang,Wang Jing,Liu Changsheng
DOI: https://doi.org/10.3389/conf.fbioe.2016.01.02667
IF: 5.7
2016-01-01
Frontiers in Bioengineering and Biotechnology
Abstract:Event Abstract Back to Event Enhanced vascularization of VEGF synergizing with 2-N,6-O-sulfated chitosan Yuanman Yu1, 2, Rui Chen1, 2, Xiang Peng2, Jing Wang1, 2, 3 and Changsheng Liu1, 2, 3 1 East China University of Science and Technology, The State Key Laboratory of Bioreactor Engineering, China 2 East China University of Science and Technology, Engineering Research Center for Biomedical Materials of Ministry of Education, China 3 East China University of Science and Technology, Key Laboratory for Ultrafine Materials of Ministry of Education, China Introduction: Rapid and controlled vascularization of engineered tissues remains one of the key limitations in tissue engineering applications[1],[2]. While vascular endothelial growth factor (VEGF) which regards as an angiogenic regulator holds greatest potential to promote angiogenesis[3]. However, soluble VEGF will be quickly degraded by enzymes in vivo and clinical applications with high dose of VEGF are often associated with severe side effects[4],[5]. Thus, reducing the dosage of VEGF and enhancing its activity becomes particularly important. 2-N,6-O-sulfated chitosan (26SCS) as a synthetic sulfated polysaccharide has been demonstrated that it could efficiently associate with VEGF to promote angiogenesis in vitro during our previous work[6]. Nevertheless, the mechanism of the interaction between 26SCS and VEGF is not clear. This study aimed at the synergy of 26SCS with VEGF as well as its pro-angiogenesis in vitro and in vivo. Materials and Methods: Human umbilical vein endothelial cells (HUVECs) which purchased from the American Type Culture Collection was used as a cell model. A series concentrations of 26SCS was used to characterize the interaction with VEGF (2 ng/mL) on cell viability. Subsequently, two experimental groups which named as 40 SCS/VEGF (26SCS, 40 ng/mL) and 160 SCS/VEGF (26SCS, 160 ng/mL) respectively were chosen to investigate the cell migration, sprouting and qRT-PCR analysis in vitro. Furthermore, we employed the corresponding concentration ratio of 26SCS and VEGF to further investigate the pro-angiogenesis activity in vivo. Subcutaneous implantation of mice (VEGF, 100 ng) and chicken chorioallantoic membrane (CAM) assay (VEGF, 20 ng) were used as experimental models, respectively. Results and Discussion: The pro-angiogenesis of 26SCS synergizing with VEGF was found and mainly studied. As shown in Figure 1, 26SCS synergizing with VEGF could directly improve HUVECs cell proliferation through dose-dependently regulating the expression of relevant angiogenic genes, and the group of 40 SCS/VEGF exhibited optimal results. Moreover, the repaired area of 40 SCS/VEGF was almost 1.5 folds compared to negative control in scratch wound healing assay, and 40 SCS/VEGF generated more branch points and forming tubes in capillary-like tube formation assay. In addition, using gelatin sponge loaded with VEGF and different content of 26SCS as samples implanted in subcutaneous model of mice, we investigated the influence of 26SCS and VEGF facilitate vascularization in vivo at day 7 (Figure 2A). The results of histological analysis showed that 26SCS and VEGF could significantly promote the repair rate of vascular network at the defect site (Figure 2B). Through the CAM assay by implanting filter paper containing different ratios of 26SCS and VEGF compounds into fertilized eggs (Figure 2C), the results further revealed that 26SCS synergizing VEGF could signally promote angiogenesis. Conclusions: In this study, 26SCS was demonstrated that synergizing with VEGF could significantly promote angiogenesis in vitro and in vivo. This findings evidence that 26SCS have the potential to improve the VEGF activity and will be promising prospects as a synergistic factor of VEGF for vascularization in clinical applications. The National Basic Research Program of China (973 Program, No. 2012CB933600); The National Natural Science Foundation of China (Grant Nos. 31271011, 31330028, and 31470923); The New Century Excellent Talents in University (Grant No. NCET-12-0856); The National Science and Technology Support Program (Grant No. 2012BAI17B02)References:[1] Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. Journal of Investigative Dermatology Symposium Proceedings: Nature Publishing Group; 2000. p. 40-6.[2] Del Gaudio C, Baiguera S, Boieri M, Mazzanti B, Ribatti D, Bianco A, et al. Induction of angiogenesis using VEGF releasing genipin-crosslinked electrospun gelatin mats. Biomaterials. 2013;34:7754-65.[3] Ferrara N, Chen H, Davis-Smyth T, Gerber H-P, Nguyen T-N, Peers D, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Medicine. 1998;4:336-40.[4] Tayalia P, Mooney DJ. Controlled growth factor delivery for tissue engineering. Advanced Materials. 2009;21:3269-85.[5] Chung Y-I, Kim S-K, Lee Y-K, Park S-J, Cho K-O, Yuk SH, et al. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex. Journal of Controlled Release. 2010;143:282-9.[6] Yu Y, Chen J, Chen R, Cao L, Tang W, Lin D, et al. Enhancement of VEGF-Mediated Angiogenesis by 2-N, 6-O-Sulfated Chitosan-Coated Hierarchical PLGA Scaffolds. ACS Applied Materials & Interfaces. 2015;7:9982-90. Keywords: blood vessel, growth factor, Bioactivity, biofunctional molecule Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: Poster Topic: Protein interactions with biomaterials Citation: Yu Y, Chen R, Peng X, Wang J and Liu C (2016). Enhanced vascularization of VEGF synergizing with 2-N,6-O-sulfated chitosan. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.02667 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Yuanman Yu Rui Chen Xiang Peng Jing Wang Changsheng Liu Google Yuanman Yu Rui Chen Xiang Peng Jing Wang Changsheng Liu Google Scholar Yuanman Yu Rui Chen Xiang Peng Jing Wang Changsheng Liu PubMed Yuanman Yu Rui Chen Xiang Peng Jing Wang Changsheng Liu Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.